FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296188538> ?p ?o ?g. }

• W4296188538 endingPage "108901" @default.
• W4296188538 startingPage "108901" @default.
• W4296188538 abstract "This post hoc analysis of four open-label extension (OLEx) studies evaluated the long-term efficacy and safety of adjunctive perampanel in adolescent patients (aged 12 to ≤17 years) with focal-onset seizures (FOS), with/without focal to bilateral tonic-clonic seizures (FBTCS), or generalized tonic-clonic seizures (GTCS).Patients who completed one of six double-blind, placebo-controlled studies could enter one of four OLEx studies comprising a blinded Conversion Period (6-16 weeks) followed by a Maintenance Phase (27 to ≤256 weeks; perampanel dose: ≤12 mg/day). Exposure, retention, seizure outcomes, and treatment-emergent adverse events (TEAEs) were analyzed. Efficacy outcomes were analyzed using observed case and last observation carried forward (LOCF) approaches; the latter was used to account for early dropouts.The Full Analysis Set comprised 309 adolescents with FOS (FBTCS, n = 109) and 19 with GTCS, and the Safety Analysis Set comprised 311 with FOS (FBTCS, n = 110) and 19 with GTCS. Mean (standard deviation) cumulative duration of perampanel exposure (weeks) was: FOS, 77.7 (58.7); FBTCS, 88.7 (63.8); and GTCS, 97.0 (35.5). Retention rates were maintained for ≤2 years (FOS, 50.0 %; FBTCS, 57.1 %; GTCS, 41.7 %). Seizure control (median percent reduction in seizure frequency/28 days) was sustained for up to 2 years; FOS (59.4 %, n = 113), FBTCS (64.6 %, n = 53), and GTCS (86.5 %, n = 17). At Year 2, 50 % responder rates were: FOS, 58.4 % (n = 66); FBTCS, 54.7 % (n = 29); and GTCS, 82.4 % (n = 14); seizure-freedom rates were: FOS, 5.3 % (n = 6); FBTCS, 24.5 % (n = 13); and GTCS, 35.3 % (n = 6). Long-term seizure control was observed even in LOCF analyses. The incidence of TEAEs was highest during Year 1 (FOS, n = 269 [86.5 %]; FBTCS, n = 95 [86.4 %]; GTCS, n = 15 [78.9 %]), compared with Years 2-4; the most common (≥10 % of patients) were dizziness, somnolence, and nasopharyngitis. No new safety signals emerged with long-term treatment.This post hoc analysis suggests that long-term (≤2 years) adjunctive perampanel (≤12 mg/day) is efficacious and generally well tolerated in adolescent patients with FOS, with or without FBTCS, or GTCS." @default.
• W4296188538 created "2022-09-18" @default.
• W4296188538 creator A5015881339 @default.
• W4296188538 creator A5018971404 @default.
• W4296188538 creator A5020477271 @default.
• W4296188538 creator A5025122018 @default.
• W4296188538 creator A5040378349 @default.
• W4296188538 creator A5089756778 @default.
• W4296188538 date "2022-10-01" @default.
• W4296188538 modified "2023-10-11" @default.
• W4296188538 title "Assessment of the long-term efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of open-label extension studies" @default.
• W4296188538 cites W1488798108 @default.
• W4296188538 cites W1498758291 @default.
• W4296188538 cites W1551373999 @default.
• W4296188538 cites W1862220344 @default.
• W4296188538 cites W1985163828 @default.
• W4296188538 cites W2022070576 @default.
• W4296188538 cites W2023205599 @default.
• W4296188538 cites W2038975845 @default.
• W4296188538 cites W2048491067 @default.
• W4296188538 cites W2070351394 @default.
• W4296188538 cites W2081618880 @default.
• W4296188538 cites W2083402915 @default.
• W4296188538 cites W2084645172 @default.
• W4296188538 cites W2087944838 @default.
• W4296188538 cites W2096356987 @default.
• W4296188538 cites W2125029005 @default.
• W4296188538 cites W2134947937 @default.
• W4296188538 cites W2135808877 @default.
• W4296188538 cites W2146599781 @default.
• W4296188538 cites W2180981774 @default.
• W4296188538 cites W2217932554 @default.
• W4296188538 cites W2367812079 @default.
• W4296188538 cites W2772236704 @default.
• W4296188538 cites W2796760753 @default.
• W4296188538 cites W2796976931 @default.
• W4296188538 cites W2998806808 @default.
• W4296188538 cites W3041697525 @default.
• W4296188538 cites W3189873252 @default.
• W4296188538 cites W4205388612 @default.
• W4296188538 cites W4206917559 @default.
• W4296188538 cites W4213110280 @default.
• W4296188538 doi "https://doi.org/10.1016/j.yebeh.2022.108901" @default.
• W4296188538 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36122531" @default.
• W4296188538 hasPublicationYear "2022" @default.
• W4296188538 type Work @default.
• W4296188538 citedByCount "4" @default.
• W4296188538 countsByYear W42961885382023 @default.
• W4296188538 crossrefType "journal-article" @default.
• W4296188538 hasAuthorship W4296188538A5015881339 @default.
• W4296188538 hasAuthorship W4296188538A5018971404 @default.
• W4296188538 hasAuthorship W4296188538A5020477271 @default.
• W4296188538 hasAuthorship W4296188538A5025122018 @default.
• W4296188538 hasAuthorship W4296188538A5040378349 @default.
• W4296188538 hasAuthorship W4296188538A5089756778 @default.
• W4296188538 hasBestOaLocation W42961885381 @default.
• W4296188538 hasConcept C118552586 @default.
• W4296188538 hasConcept C126322002 @default.
• W4296188538 hasConcept C142724271 @default.
• W4296188538 hasConcept C15744967 @default.
• W4296188538 hasConcept C187212893 @default.
• W4296188538 hasConcept C197934379 @default.
• W4296188538 hasConcept C204787440 @default.
• W4296188538 hasConcept C27081682 @default.
• W4296188538 hasConcept C2778186239 @default.
• W4296188538 hasConcept C2780836401 @default.
• W4296188538 hasConcept C2992886853 @default.
• W4296188538 hasConcept C3018162438 @default.
• W4296188538 hasConcept C42219234 @default.
• W4296188538 hasConcept C67761136 @default.
• W4296188538 hasConcept C71924100 @default.
• W4296188538 hasConceptScore W4296188538C118552586 @default.
• W4296188538 hasConceptScore W4296188538C126322002 @default.
• W4296188538 hasConceptScore W4296188538C142724271 @default.
• W4296188538 hasConceptScore W4296188538C15744967 @default.
• W4296188538 hasConceptScore W4296188538C187212893 @default.
• W4296188538 hasConceptScore W4296188538C197934379 @default.
• W4296188538 hasConceptScore W4296188538C204787440 @default.
• W4296188538 hasConceptScore W4296188538C27081682 @default.
• W4296188538 hasConceptScore W4296188538C2778186239 @default.
• W4296188538 hasConceptScore W4296188538C2780836401 @default.
• W4296188538 hasConceptScore W4296188538C2992886853 @default.
• W4296188538 hasConceptScore W4296188538C3018162438 @default.
• W4296188538 hasConceptScore W4296188538C42219234 @default.
• W4296188538 hasConceptScore W4296188538C67761136 @default.
• W4296188538 hasConceptScore W4296188538C71924100 @default.
• W4296188538 hasLocation W42961885381 @default.
• W4296188538 hasLocation W42961885382 @default.
• W4296188538 hasOpenAccess W4296188538 @default.
• W4296188538 hasPrimaryLocation W42961885381 @default.
• W4296188538 hasRelatedWork W2060121528 @default.
• W4296188538 hasRelatedWork W2561337999 @default.
• W4296188538 hasRelatedWork W2808594719 @default.
• W4296188538 hasRelatedWork W2889190621 @default.
• W4296188538 hasRelatedWork W2985476322 @default.
• W4296188538 hasRelatedWork W3029872667 @default.
• W4296188538 hasRelatedWork W4233172917 @default.
• W4296188538 hasRelatedWork W4288033808 @default.

• next